COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test
Morgan Stanley Says Edwards Lifesciences Settlement With Abbott An 'Expensive Positive'
COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test
Morgan Stanley Says Edwards Lifesciences Settlement With Abbott An 'Expensive Positive'
Analysts Constructive On Intuitive Surgical Following Solid Quarter
Analysts, Investors Like Johnson & Johnson's Improvement, But Lawsuits Loom
Analysts Constructive On Intuitive Surgical Following Solid Quarter
Analysts, Investors Like Johnson & Johnson's Improvement, But Lawsuits Loom
Sell-Side Positive On Johnson & Johnson's Unexpected Ohio Opioid Settlement
Why One Johnson & Johnson Analyst Sees Oklahoma Opioid Ruling As Near-Term Sentiment Positive
David Lewis Recent News
Intuitive Surgical's Q2 Performance Lauded By Bullish Analysts
After Earnings Beat, Wall Street Talks Johnson & Johnson Litigation Risk
Morgan Stanley: Medtronic's $4B Financing Could Be 10-Cent EPS Tailwind
Johnson & Johnson Analysts Laud Accelerating Pharma Business
Analysts View Johnson & Johnson's Organic Growth Guidance As Conservative
Analysts Unfazed By Intuitive Surgical's Higher Opex Guidance
Analysts Stand By Johnson & Johnson Despite Earnings Pullback
Morgan Stanley Finds A Few Reasons To Double Upgrade Baxter
Morgan Stanley Downgrades Hologic On Tough Cynosure Recovery, Surgery Business Risks
Johnson & Johnson's Asbestos Woes: Experts Speak Up
3 Reasons Why Nevro Corp. Was Downgraded By Morgan Stanley
Analyst: Intuitive Surgical Is Moving Into Its 'Most Catalyst Rich' Cycle Ever
Abbott Labs Has 'An Emerging Picture Of Top-Tier Growth,' Says Morgan Stanley
Morgan Stanley Turns Bullish On Haemonetics
On The Detroit River, America's Only Floating Post Office Blends Tradition And Technology
Intuitive Surgical's Sp Ushers In The Next Phase Of Growth Story
Here's Every Sell-Side Rating Following iRhythm's IPO Quiet Period Expiration
Hill-Rom Story Not Appreciated By Wall Street, Says Morgan Stanley
Nevro Has A Multi-Billion Dollar Opportunity
Johnson & Johnson Sales Fall: What The Street Is Saying Now
Everyone's Talking About ROLARR Heading Into Intuitive Surgical Earnings: Here's What It Means
Johnson & Johnson Faces Pressure From U.S. Patent Office
UPDATE: Morgan Stanley Initiates Coverage On Intuitive Surgical